Athira pharma announces publication in journal of alzheimer's disease highlighting need for novel alzheimer's disease treatment approaches and potential of enhancing hgf/met pathway

Bothell, wash., feb. 01, 2023 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of a review paper highlighting the need for novel treatment approaches to address alzheimer's disease and the therapeutic potential of fosgonimeton, one of the company's novel small molecule positive modulators of the hgf/met system. the review article titled, “the case for a novel therapeutic approach to dementia: small molecule hepatocyte growth factor (hgf/met) positive modulators,” was published online in the peer-reviewed journal, journal of alzheimer's disease.
ATHA Ratings Summary
ATHA Quant Ranking